PegLiposomal Doxorubicin + Carboplatin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mesenchymal Tumor
Conditions
Mesenchymal Tumor, Carcinosarcoma, Leiomyosarcoma
Trial Timeline
Jun 1, 2008 → Jan 1, 2012
NCT ID
NCT00815945About PegLiposomal Doxorubicin + Carboplatin
PegLiposomal Doxorubicin + Carboplatin is a phase 2 stage product being developed by Merck for Mesenchymal Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT00815945. Target conditions include Mesenchymal Tumor, Carcinosarcoma, Leiomyosarcoma.
What happened to similar drugs?
0 of 1 similar drugs in Mesenchymal Tumor were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00815945 | Phase 2 | Completed |
Competing Products
1 competing product in Mesenchymal Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Remestemcel-L + Placebo | Mesoblast | Phase 3 | 26 |